An emerging biotech with transformative potential

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.

Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.

Anocca’s powerful technologies are also being deployed to develop a range of novel therapeutic and prophylactic products in oncology, infectious disease and autoimmunity.